2026 Appendix 4E and Annual Report
Filed with ASX · · 51 pages · English
Summary by 6ix AI
The report indicates a significant increase in revenue from ordinary activities, while the loss after tax has decreased compared to the previous period. The company has also noted a successful capital raising effort aimed at expanding its product portfolio and improving operational efficiencies. Additionally, there has been a leadership change with the appointment of Cheri Walker as Interim Chief Executive Officer following John Kelly's resignation.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Story so far
Earlier from Atomo Diagnostics
- Managing Director & CEO Transition
- Share Purchase Plan Results
- Response to ASX Aware Letter
- Atomo Completes Capital Raise
- FebriDx FDA CLIA wavier approval unlocks upside for Pascal
Later from Atomo Diagnostics
- Atomo Signs Agreement with Innovation Scientific
- Quarterly Activities/Appendix 4C Cash Flow Report
- Q1 FY27 Results Presentation
Follow Atomo Diagnostics into a list and get an email when it puts out news.
Follow Atomo Diagnostics